Outcomes Research in Cancer Clinical Trial Cooperative Groups: the RTOG Model

Overview

Journal Qual Life Res

Specialties Pharmacology
Rehabilitation Medicine

Date 2004 Aug 4

PMID 15287270

Citations 9

Authors

D W Bruner

B Movsas

A Konski

M Roach

M Bondy

C Scarintino

C Scott

W Curran

Affiliations

Soon will be listed here.

Abstract

Background: The Radiation Therapy Oncology Group (RTOG), a National Cancer Institute sponsored cancer clinical trials research cooperative, has recently formed an Outcomes Committee to assess a comprehensive array of clinical trial endpoints and factors impacting the net effect of therapy.

Methods: To study outcomes in a consistent, comprehensive and coordinated manner, the RTOG Outcomes Committee developed a model to assess clinical, humanistic, and economic outcomes important in clinical trials.

Results: This paper reviews how the RTOG incorporates outcomes research into cancer clinical trials, and demonstrates utilization of the RTOG Outcomes Model to test hypotheses related to non-small-cell lung cancer (NSCLC). In this example, the clinical component of the model indicates that the addition of chemotherapy to radiotherapy (RT) improves survival but increases the risk of toxicity. The humanistic component indicates that esophagitis is the symptom impacting quality of life the greatest and may outweigh the benefits in elderly (> or =70 years) patients. The economic component of the model indicates that accounting for quality-adjusted survival, concurrent chemoRT for the treatment of NSCLC is within the range of economically acceptable recommendations.

Conclusion: The RTOG Outcomes Model guides a comprehensive program of research that systematically measures a triad of endpoints considered important to clinical trials research.

Citing Articles

Symptom science research conducted in community programs funded by the US National Cancer Institute: a 12-year review, 2008 to 2019.

St Germain D, McCaskill Stevens W, OMara A Support Care Cancer. 2022; 30(6):4739-4746.

PMID: 35122531 DOI: 10.1007/s00520-022-06875-0.

A Novel Methodology using CT Imaging Biomarkers to Quantify Radiation Sensitivity in the Esophagus with Application to Clinical Trials.

Niedzielski J, Yang J, Stingo F, Liao Z, Gomez D, Mohan R Sci Rep. 2017; 7(1):6034.

PMID: 28729729 PMC: 5519548. DOI: 10.1038/s41598-017-05003-x.

Radical hypo-fractionated radiotherapy with volumetric modulated arc therapy in lung cancer : A retrospective study of elderly patients with stage III disease.

Franceschini D, De Rose F, Cozzi L, Navarria P, Clerici E, Franzese C Strahlenther Onkol. 2017; 193(5):385-391.

PMID: 28168322 DOI: 10.1007/s00066-017-1103-3.

(18)F-Fluorodeoxyglucose Positron Emission Tomography Can Quantify and Predict Esophageal Injury During Radiation Therapy.

Niedzielski J, Yang J, Liao Z, Gomez D, Stingo F, Mohan R Int J Radiat Oncol Biol Phys. 2016; 96(3):670-8.

PMID: 27681764 PMC: 5117825. DOI: 10.1016/j.ijrobp.2016.07.012.

Objectively Quantifying Radiation Esophagitis With Novel Computed Tomography-Based Metrics.

Niedzielski J, Yang J, Stingo F, Martel M, Mohan R, Gomez D Int J Radiat Oncol Biol Phys. 2015; 94(2):385-93.

PMID: 26675063 PMC: 4747797. DOI: 10.1016/j.ijrobp.2015.10.010.

References

Bezjak A, Dixon P, Brundage M, Tu D, Palmer M, Blood P . Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). Int J Radiat Oncol Biol Phys. 2002; 54(3):719-28. DOI: 10.1016/s0360-3016(02)02989-9. View

Bruner D . In search of the "quality" in quality-of-life research. Int J Radiat Oncol Biol Phys. 1995; 31(1):191-2. DOI: 10.1016/0360-3016(94)00358-R. View

Mandelblatt J, Eisenberg J . Historical and methodological perspectives on cancer outcomes research. Oncology (Williston Park). 1995; 9(11 Suppl):23-32. View

Gregor A, Cull A, Stephens R, Kirkpatrick J, Yarnold J, Girling D . Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European.... Eur J Cancer. 1998; 33(11):1752-8. DOI: 10.1016/s0959-8049(97)00135-4. View

Pignon J, Stewart L . Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: a meta-analysis. Cancer. 1996; 77(11):2413-4. DOI: 10.1002/(SICI)1097-0142(19960601)77:11<2413::AID-CNCR34>3.0.CO;2-Y. View

Anton-Culver H, FELDSTEIN P . Treatment differences and other prognostic factors related to breast cancer survival. Delivery systems and medical outcomes. JAMA. 1994; 271(15):1163-8. View

Cella D, Orofiamma B, Holland J, Silberfarb P, Tross S, FELDSTEIN M . The relationship of psychological distress, extent of disease, and performance status in patients with lung cancer. Cancer. 1987; 60(7):1661-7. DOI: 10.1002/1097-0142(19871001)60:7<1661::aid-cncr2820600740>3.0.co;2-4. View

Hanks , Coia , Curry . Patterns of Care Studies: Past, Present, and Future. Semin Radiat Oncol. 1997; 7(2):97-100. DOI: 10.1053/SRAO00700097. View

Neymark N, Adriaenssen I . The costs of managing patients with advanced colorectal cancer in 10 different European centres. Eur J Cancer. 2000; 35(13):1789-95. DOI: 10.1016/s0959-8049(99)00216-6. View

10.

Neymark N . Techniques for health economics analysis in oncology: Part 1. Crit Rev Oncol Hematol. 1999; 30(1):1-11. DOI: 10.1016/s1040-8428(98)00026-2. View

11.

Finkelstein D, Cassileth B, Bonomi P, Ruckdeschel J, Ezdinli E, Wolter J . A pilot study of the Functional Living Index-Cancer (FLIC) Scale for the assessment of quality of life for metastatic lung cancer patients. An Eastern Cooperative Oncology Group study. Am J Clin Oncol. 1988; 11(6):630-3. DOI: 10.1097/00000421-198812000-00007. View

12.

Murray K, Nelson D, Scott C, Fischbach A, Porter A, Farnan N . Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02. Int J Radiat Oncol Biol Phys. 1995; 31(3):453-9. DOI: 10.1016/0360-3016(95)93160-9. View

13.

Kelly K, Crowley J, Bunn Jr P, Presant C, Grevstad P, Moinpour C . Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001; 19(13):3210-8. DOI: 10.1200/JCO.2001.19.13.3210. View

14.

Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E . Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000; 18(3):623-31. DOI: 10.1200/JCO.2000.18.3.623. View

15.

Fairclough D, Fetting J, Cella D, Wonson W, Moinpour C . Quality of life and quality adjusted survival for breast cancer patients receiving adjuvant therapy. Eastern Cooperative Oncology Group (ECOG). Qual Life Res. 2000; 8(8):723-31. DOI: 10.1023/a:1008806828316. View

16.

Norris B, Pritchard K, JAMES K, Myles J, Bennett K, Marlin S . Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol. 2000; 18(12):2385-94. DOI: 10.1200/JCO.2000.18.12.2385. View

17.

Kornblith A, Herndon 2nd J, Silverman L, Demakos E, Odchimar-Reissig R, Holland J . Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002; 20(10):2441-52. DOI: 10.1200/JCO.2002.04.044. View

18.

Neymark N, Adriaenssen I, Gorlia T, Caleo S, Bolla M, Brochon D . Cost-effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer: results decisively determined by the cut-off time-point chosen for the analysis. Eur J Cancer. 2001; 37(14):1768-74. DOI: 10.1016/s0959-8049(01)00197-6. View

19.

Herndon 2nd J, Fleishman S, Kornblith A, Kosty M, Green M, Holland J . Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma?. Cancer. 1999; 85(2):333-40. DOI: 10.1002/(sici)1097-0142(19990115)85:2<333::aid-cncr10>3.0.co;2-q. View

20.

Hill J, Kornblith A, Jones D, Freeman A, HOLLAND J, GLICKSMAN A . A comparative study of the long term psychosocial functioning of childhood acute lymphoblastic leukemia survivors treated by intrathecal methotrexate with or without cranial radiation. Cancer. 1998; 82(1):208-18. View